| name | es-check-bmd-indication |
| description | Determines whether bone mineral density (BMD) measurement is indicated when patients have osteoporosis risk factors or have discontinued sex hormone therapy following gonadectomy. Clinical triggers include documented osteoporosis risk factors (e.g., low body weight, glucocorticoid use, prior fracture) or cessation of sex hormone therapy after surgical gonadectomy. |
Check if bone mineral density measurement is indicated
STEP 1 — Gather Information
Collect patient history: presence of osteoporosis risk factors (low body weight <60 kg, prior fragility fracture, chronic glucocorticoid use, hypogonadism, malabsorption, smoking, alcohol excess, family history of osteoporosis) and whether sex hormone therapy has been stopped after gonadectomy (orchiectomy, oophorectomy).
STEP 2 — Rule In / Rule Out
If any osteoporosis risk factor is present OR sex hormone therapy has been discontinued after gonadectomy → proceed to Step 3; otherwise → BMD measurement not indicated.
STEP 3 — Classify or Stratify
Classify as BMD indicated (no further stratification needed per guideline).
STEP 4 — Decide
Order dual-energy X-ray absorptiometry (DXA) scan of lumbar spine and hip; repeat monitoring per clinical judgment or as per Table 7/9 in guideline (every 1–2 years if indicated).
Clinical Guardrails / Mimics / Pitfalls
Do not order BMD solely based on transgender status without risk factors; interpret BMD using reference ranges for sex assigned at birth pending further data; avoid delaying BMD in patients on long-term hormone therapy who develop risk factors; ensure gonadectomy status is confirmed (surgical removal of gonads) before attributing indication to hormone cessation.
Concrete Clinical Example
A 28-year-old transgender female underwent orchiectomy and stopped estrogen therapy 6 months ago; she has a BMI of 18 kg/m2 and reports a prior wrist fracture. Risk factors present → BMD DXA ordered shows T-score -2.1 at lumbar spine, leading to initiation of osteoporosis treatment.
Source: Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons, Endocrine Society, 2017, DOI:10.1210/jc.2017-01658
